This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
20 Sep 2022

Solvias Acquires Cergentis to Bolster Biologics and Cell & Gene Therapy Capabilities

Cergentis enables Solvias to provide customers with proprietary technology and knowledge steeped in fast-evolving genomic techniques that support effective decision-making and R&D program design.

News Summary

- Solvias, one of the world’s leading independent pharmaceutical testing and manufacturing companies, has acquired Netherlands-based Cergentis to bolster its biologics and cell & gene therapy testing capabilities.

- With global sales of cell & gene therapies projected to accelerate at a 63% compound annual growth rate, more researchers require sophisticated solutions to validate the safety & efficacy of these advanced new therapies.

- Cergentis enables Solvias to provide customers with proprietary technology and knowledge steeped in fast-evolving genomic techniques that support effective decision-making and R&D program design.

Mentioned Companies
Solvias AG
View company profile